A question for the more learned on the forum....
In the case of GVHD, we know that we can market a product in Japan after phase 2 trials. Is this only the case for certain (life threatening) illnesses, or could CYP market OA treatments in Japan on their own after a successful phase 2 trial next year?
Ann: CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial, page-49
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.74M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 22.5¢ | 22.0¢ | $29.06K | 131.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 951 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| CYP (ASX) Chart |